The failure of the concurrent chemo-immuno-radiation approach has not stalled progress. Instead, new clinical trials are actively exploring novel strategies like SBRT boosts, dual checkpoint inhibitors, radiosensitizing nanoparticles, and induction immunotherapy to improve upon the current standard of care.

Instead of basing adjuvant radiation decisions on a patient's initial, pre-treatment tumor stage, clinicians should use the post-neoadjuvant pathological stage (ypTNM). Patients with a major pathologic response (e.g., downstaging from T3 to T1) may be able to safely avoid additional adjuvant radiation therapy.

A leading hypothesis for why adding immunotherapy to chemoradiation failed is that radiation, particularly for central tumors, destroys the very lymphocytes immunotherapy aims to activate. This biological mechanism suggests the radiation essentially canceled out the drug's intended effect.

The primary goal after managing immune checkpoint inhibitor (ICI)-induced ITP is resuming cancer therapy. Data shows most patients do not experience a relapse of ITP upon re-challenge with the ICI, allowing them to continue their effective cancer treatment.

For patients with otherwise well-controlled disease who develop isolated oligoprogression in the brain, evidence suggests a better survival outcome from adding local therapy (like SRS) and continuing the current effective systemic therapy, rather than switching the systemic regimen entirely.

For endometrial or cervical cancer patients who progress after receiving a checkpoint inhibitor, re-challenging with a single-agent immunotherapy is a less desirable approach. Emerging data suggests that a combination therapy—such as an ICI paired with a TKI like lenvatinib or a bispecific antibody—offers a more promising chance of response.

Experts express strong confidence in the effectiveness of radiation therapy for epithelioid sarcomas, noting the tumors are very sensitive to it. In difficult locally advanced cases, radiation is a key modality for gaining disease control and managing pain, with growing interest in combining it with immunotherapy to enhance its effects.

For patients who previously received immunotherapy (IO), a recurrence more than 12 months after completing treatment makes re-challenging with an IO agent a reasonable option. The likelihood of benefit is lower if the recurrence is within 6-12 months and minimal if under 6 months.

Data shows that patients who permanently stopped ipilimumab due to immune-related side effects still had exceptionally good outcomes. This gives clinicians confidence to manage toxicity by discontinuing the CTLA-4 inhibitor portion of the regimen while continuing nivolumab, without fearing a loss of efficacy.